News

1 2
NEWS

SOTIO Announces Upcoming Poster Presentations at the 2024 SITC Annual Meeting

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November 6 - 10, 2024, in Houston, TX.

NEWS

SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors

  • Novel immunocytokine utilizes dual mechanisms of action to activate immune system to fight solid tumors;
  • Company has received IND and CTA approval to initiate Phase 1 study in the U.S. and Europe.

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced the dosing of the first patient in its Phase 1, first-in-human clinical trial evaluating SOT201, a next-generation PD-1-targeting immunocytokine. The VICTORIA-01 study will evaluate the safety, tolerability and initial efficacy of SOT201 monotherapy for the treatment of advanced solid tumors. 

NEWS

SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California.